HRTX - Heron Therapeutics Inc.: The Losing Streak Continues (HRTX)
Heron Therapeutics Inc. (NASDAQ:HRTX) traded today at a new 52-week low of $12.20. Approximately 223,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.
Heron Therapeutics Inc. (NASDAQ:HRTX) has potential upside of 0.7% based on a current price of $12.41 and analysts' consensus price target of $12.50.
In the past 52 weeks, Heron Therapeutics Inc. share prices are bracketed by a current low of $12.20 and a high of $22.40 and is now at $12.41.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer